Tumor News and Research

RSS

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that it has amended and expanded the scope of the protocol PV-10-LC-01, "A Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics of PV-10 Chemoablation of Cancer Metastatic to the Liver or Hepatocellular Carcinoma not Amenable to Resection or Transplant."

28 Sep 2012

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

For a cancer patient, over-expression of the MYC oncogene is a bad omen. Scientists have long known that in tumor cells, elevated levels of MYC's protein product, c-Myc, are associated with poor clinical outcomes, including increased rates of metastasis, recurrence, and mortality. Yet decades of research producing thousands of scientific papers on the subject have failed to consistently explain precisely how c-Myc exerts its effects across a broad range of cancer types. Until now, that is.

28 Sep 2012

Loyola offers corrective surgeries for adults with strabismus

Since she was a child, Katie Szymczak has had eyes that wandered. Her right eye, which was the worst, would look up and to the side, rather than straight ahead. Her husband affectionately called them "googly eyes." But other people could be mean. "They would say to me, 'What's wrong with your eyes, why aren't you looking at me?'" Szymczak said. "It really hurt a lot."

28 Sep 2012

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

Using a newly discovered cell technology, Georgetown University Medical Center researchers were able to identify an effective therapy for a patient with a rare type of lung tumor. The single case study, reported in the September 27 issue of New England Journal of Medicine, provides a snapshot of the new technology's promising potential; however, researchers strongly caution that it could be years before validation studies are completed and regulatory approval received for its broader use.

28 Sep 2012

UNMCC to investigate R-ketorolac use against ovarian cancer cells

Most drugs take ten years-and frequently, more-to go from concept to FDA approval. One way to reduce this time investment is to look for already-approved drugs that could be put to new uses. And that's just what Angela Wandinger-Ness, PhD, UNM Professor of Pathology, and Laurie Hudson, PhD, UNM Professor of Pharmaceutical Sciences, have done.

28 Sep 2012

UNMCC researcher to investigate possible mechanism for cancer tumor development

Most of us think of DNA mutations as the culprits that cause cancer. Scott Ness, PhD, University of New Mexico Professor of Molecular Genetics and Microbiology and Associate Director at the UNM Cancer Center, thinks there may be another, more elusive culprit. If Dr. Ness is right his research, funded as part of the National Cancer Institute's Provocative Questions Project, might open a whole new arena in which to target anticancer drugs.

28 Sep 2012

Recovery from single-site laparoscopy is less painful for kidney cancer patients

Researchers at the University of California, San Diego School of Medicine have found that recovery from an emerging, minimally invasive surgical technique called Laparo-Endoscopic Single-Site Surgery (LESS) was less painful for kidney cancer patients than traditional laparoscopic surgery.

28 Sep 2012

UCSD receives NCI grant to continue research into chronic lymphocytic leukemia

An international consortium of scientists studying chronic lymphocytic leukemia (CLL), based at the University of California, San Diego School of Medicine, has been awarded a 5-year, $20 million grant by the National Cancer Institute, part of the National Institutes of Health.

28 Sep 2012

Study explores effects of immunotherapy on malignant gliomas

In what could be a breakthrough in the treatment of deadly brain tumors, a team of researchers from Barrow Neurological Institute and Arizona State University has discovered that the immune system reacts differently to different types of brain tissue, shedding light on why cancerous brain tumors are so difficult to treat.

28 Sep 2012

Longer looks: In-depth in the ER; Brains are saved as high school football season begins

Eric Morgan, in his 20s and planning to get married, arrives at Highland Hospital's emergency room, shaken that he has been diagnosed with a testicular tumor that is likely cancer. Surgeons at a private hospital have turned him away for lack of insurance but tell him it's "urgent" he get care.

28 Sep 2012

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

The U.S. Food and Drug Administration today approved Stivarga (regorafenib) to treat patients with colorectal cancer that has progressed after treatment and spread to other parts of the body (metastatic).

28 Sep 2012

High-dose, pulsed-dose BRT feasible palliative options in laryngeal cancer

High-dose and pulsed-dose brachytherapy are feasible options for laryngeal cancer patients with recurrent or residual stomal tumor after total laryngectomy, report Polish researchers.

27 Sep 2012

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

Robotic surgery though the mouth is a safe and effective way to remove tumors of the throat and voice box, according to a study by head and neck cancer surgeons at the Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.

27 Sep 2012

DNp63a protein employs epigenetics to keep cancer cells alive

Squamous cell carcinoma (SCC) is diagnosed in about 700,000 people in the United States every year. Commonly contributing to SCC is a protein called DNp63a - it goes abnormally high and the ability of a patient's body to kill cancer cells goes abnormally low. In many cases of SCC, it's just that simple. And science thought the function of DNp63a was simple, as well: the tumor suppressor gene p53 is responsible for recognizing and killing cancer cells, and in SCC, it's usually inactivated. It looked like high DNp63a repressed p53, made SCC.

27 Sep 2012

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

Researchers at Kansas State University have developed a simple blood test that can accurately detect the beginning stages of cancer.

27 Sep 2012

New optical imaging technology could aid in breast cancer diagnosis and treatment

New optical imaging technology developed at Tufts University School of Engineering could give doctors new ways to both identify breast cancer and monitor individual patients' response to initial treatment of the disease.

27 Sep 2012

Henry Ford Hospital opens new Center for Cancer Surgery

With more patients seeking cancer treatment – especially surgery – than ever before, Henry Ford Hospital has opened the new Center for Cancer Surgery.

27 Sep 2012

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Flow cytometry isolates stem cells from brain tumors

A new video protocol in Journal of Visualized Experiments (JoVE) details an assay to identify brain tumor initiating stem cells from primary brain tumors. Through flow cytometry, scientists separate stem cells from the rest of the tumor, allowing quick and efficient analysis of target cells. This approach has been effectively used to identify similar stem cells in leukemia patients.

26 Sep 2012

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

UC Davis cancer researchers have discovered significant differences in radiation-therapy response among patients with oropharyngeal cancer depending on whether they carry the human papillomavirus (HPV), a common sexually transmitted virus. The findings, published online today in The Laryngoscope Journal, could lead to more individualized radiation treatment regimens, which for many patients with HPV could be shorter and potentially less toxic.

26 Sep 2012

Tumor News and Research

Provectus amends and expands protocol for PV-10 Phase 1 hepatocellular carcinoma study

Elevated c-Myc expression amplifies gene activity in tumor cells of multiple cancer types

Loyola offers corrective surgeries for adults with strabismus

Conditionally reprogrammed cells help identify effective therapy for HPV-positive RRP

UNMCC to investigate R-ketorolac use against ovarian cancer cells

UNMCC researcher to investigate possible mechanism for cancer tumor development

Recovery from single-site laparoscopy is less painful for kidney cancer patients

UCSD receives NCI grant to continue research into chronic lymphocytic leukemia

Study explores effects of immunotherapy on malignant gliomas

Longer looks: In-depth in the ER; Brains are saved as high school football season begins

Bayer HealthCare receives FDA approval for Stivarga to treat colorectal cancer

High-dose, pulsed-dose BRT feasible palliative options in laryngeal cancer

Report illustrates safety and efficacy of transoral robotic surgery for supraglottic laryngectomy

DNp63a protein employs epigenetics to keep cancer cells alive

KSU creates simple blood test that can accurately detect lung and breast cancer’s early stages

New optical imaging technology could aid in breast cancer diagnosis and treatment

Henry Ford Hospital opens new Center for Cancer Surgery

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Flow cytometry isolates stem cells from brain tumors

HPV-positive oropharyngeal cancer patients have more rapid and robust radiation-therapy response

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News